Sernova (SVA) Competitors

Aptose Biosciences (TSE:APS) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Does the MarketBeat Community prefer APS or SVA?

Aptose Biosciences received 202 more outperform votes than Sernova when rated by MarketBeat users. However, 91.67% of users gave Sernova an outperform vote while only 72.20% of users gave Aptose Biosciences an outperform vote.

Company	Underperform	Outperform
Aptose Biosciences	Outperform Votes 213 72.20%	Underperform Votes 82 27.80%
Sernova	Outperform Votes 11 91.67%	Underperform Votes 1 8.33%

Does the media prefer APS or SVA?

In the previous week, Sernova had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 2 mentions for Sernova and 1 mentions for Aptose Biosciences. Aptose Biosciences' average media sentiment score of 1.16 beat Sernova's score of -0.77 indicating that Aptose Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptose Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sernova	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Which has better valuation & earnings, APS or SVA?

Sernova is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$5.02	-0.96
Sernova	N/A	N/A	-C$35.70M	-C$0.10	-1.45

Do analysts prefer APS or SVA?

Sernova has a consensus target price of C$1.83, suggesting a potential upside of 1,122.22%. Given Sernova's higher possible upside, analysts clearly believe Sernova is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Sernova	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk & volatility, APS or SVA?

Aptose Biosciences has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.

Is APS or SVA more profitable?

Aptose Biosciences' return on equity of 1,017.48% beat Sernova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	1,017.48%	-136.29%
Sernova	N/A	473.85%	-119.26%

Do institutionals and insiders believe in APS or SVA?

15.1% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 0.1% of Sernova shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by insiders. Comparatively, 12.1% of Sernova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aptose Biosciences beats Sernova on 8 of the 15 factors compared between the two stocks.